![Darin Lippoldt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Darin Lippoldt
Präsident bei
SOLENO THERAPEUTICS, INC.
Vermögen: 9 Mio $ am 31.05.2026
Profil
Darin Michael Lippoldt is currently President, Secretary & Director at Soleno Therapeutics, Inc. since 2026.
He is also Director at Immedica Group Ltd. since 2022 and Secretary & Chief Legal Officer at Neurocrine Biosciences, Inc. since 2014.
Formerly, Mr. Lippoldt was Associate General Counsel at Amylin Pharmaceuticals, Inc. from 2003 to 2010.
From 2013 to 2014, served as Secretary, Chief Compliance Officer & Executive VP at Philips Image Guided Therapy Corp.
Education includes undergraduate and graduate degrees from St. Mary's University, with the undergraduate degree conferred in 1987.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.02.2026 | 54’729 ( 0.05% ) | 9 Mio $ | 31.05.2026 |
Aktive Positionen von Darin Lippoldt
| Unternehmen | Position | Beginn |
|---|---|---|
| NEUROCRINE BIOSCIENCES, INC. | General Counsel | 01.10.2014 |
| DIUL GROUP | Direktor/Vorstandsmitglied | 01.11.2022 |
| SOLENO THERAPEUTICS, INC. | Präsident | 15.05.2026 |
Ehemalige bekannte Positionen von Darin Lippoldt
| Unternehmen | Position | Ende |
|---|---|---|
| VOLCANO CORPORATION | Compliance Officer | 01.10.2014 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Corporate Officer/Principal | 01.07.2010 |
Ausbildung von Darin Lippoldt
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
64
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Neurocrine Biosciences, Inc.
 Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
Philips Image Guided Therapy Corp.
 Philips Image Guided Therapy Corp. Medical SpecialtiesHealth Technology Designs, develops and manufactures intravascular ultrasound products | Health Technology |
Soleno Therapeutics, Inc.
 Soleno Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes novel therapeutics for the treatment of rare diseases | Health Technology |
St. Mary's University
 St. Mary's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Diurnal Group Ltd.
 Diurnal Group Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and commercializes therapeutics for neuropsychiatric, neurological & neuroendocrine disorders | Health Technology |
